Sharon Mates Sells 34,396 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 30th. The shares were sold at an average price of $72.84, for a total value of $2,505,404.64. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $77,962,764.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech dealsSharon Mates also recently made the following trade(s): On Tuesday, August 27th, Sharon Mates sold 40,513 shares of Intra-Cellular Therapies stock. The shares were sold at an average price of $73.58, for a total value of $2,980,946.54. On Friday, August 23rd, Sharon Mates sold 28,680 shares of Intra-Cellular Therapies stock. The shares were sold at an average price of $74.46, for a total value of $2,135,512.80. On Wednesday, August 21st, Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Intra-Cellular Therapies Price PerformanceShares of ITCI traded up $1.02 during mid-day trading on Friday, reaching $73.28. 603,112 shares of the company's stock traded hands, compared to its average volume of 956,094. The stock has a market cap of $7.74 billion, a P/E ratio of -63.17 and a beta of 1.01. The stock's 50-day moving average is $75.02 and its two-hundred day moving average is $71.18. Intra-Cellular Therapies, Inc. has a 12 month low of $45.50 and a 12 month high of $84.89. Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The firm had revenue of $161.40 million for the quarter, compared to analysts' expectations of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The company's quarterly revenue was up 45.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.45) earnings per share. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.54 earnings per share for the current year. Wall Street Analysts Forecast GrowthSeveral brokerages have recently issued reports on ITCI. Mizuho lifted their target price on Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, June 21st. Royal Bank of Canada reduced their target price on Intra-Cellular Therapies from $107.00 to $106.00 and set an "outperform" rating on the stock in a report on Thursday, August 8th. Canaccord Genuity Group boosted their price objective on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a "buy" rating in a research note on Thursday, June 20th. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Finally, Needham & Company LLC reissued a "buy" rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $97.00.Get Our Latest Stock Analysis on ITCIInstitutional Trading of Intra-Cellular TherapiesA number of large investors have recently modified their holdings of ITCI. Avoro Capital Advisors LLC purchased a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $161,543,000. Norges Bank purchased a new stake in Intra-Cellular Therapies during the fourth quarter worth $85,744,000. Perceptive Advisors LLC lifted its holdings in Intra-Cellular Therapies by 62.6% during the second quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company's stock worth $117,557,000 after buying an additional 661,052 shares during the period. Millennium Management LLC lifted its holdings in Intra-Cellular Therapies by 214.5% during the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company's stock worth $60,895,000 after buying an additional 606,358 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Intra-Cellular Therapies by 6.5% during the fourth quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company's stock worth $651,334,000 after buying an additional 554,577 shares during the period. Hedge funds and other institutional investors own 92.33% of the company's stock. Intra-Cellular Therapies Company Profile (Get Free Report)Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.Recommended StoriesFive stocks we like better than Intra-Cellular TherapiesWhy Are Stock Sectors Important to Successful Investing?The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?3 Fintech Stocks With Good 2021 ProspectsAre These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes3 Natural Gas Stocks That Offer Great Dividend YieldsFive Below Stock Faces Challenges Despite Strong Revenue GrowthThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.→ Buffett’s Dirty Little Secret [EXPOSED!] (From Colonial Metals) (Ad)Should you invest $1,000 in Intra-Cellular Therapies right now?Before you consider Intra-Cellular Therapies, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.While Intra-Cellular Therapies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here